Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 400-402

  Yoshizato, Tetsuichi ^a   Nannya, Yasuhito ^a   Yoshiki, Yumiko ^a   Nakamura, Fumihiko ^a   Imai, Yoichi ^a   Ichikawa, Motoshi ^a   Kurokawa, Mineo ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Edema; Hypothyroidism; Nilotinib

Indexed keywords

IMATINIB; LEVOTHYROXINE; LIOTHYRONINE; NILOTINIB; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG INDUCED DISEASE; EDEMA; HEART FAILURE; HEART FUNCTION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; LIOTHYRONINE BLOOD LEVEL; MALE; MYELOID LEUKEMIA; NILOTINIB INDUCED HYPOTHYROIDISM; THYROGLOBULIN BLOOD LEVEL; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

AGED; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PYRIMIDINES; THYROID HORMONES;

EID: 79955818155     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0790-2     Document Type: Article

References (13)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17. (Pubitemid 44903745)
2. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-41. (Pubitemid 40248339)
3. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.
4. Takamatsu J, Yoshida S, Yokozawa T, et al. Correlation of antithyroglobulin and antithyroid-peroxidase antibody profiles with clinical and ultrasound characteristics of chronic thyroiditis. Thyroid. 1998;8:1101-6. (Pubitemid 29042542)
5. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005;78:433-8. (Pubitemid 41393678)
6. Dora JM, Leie MA, Netto B, et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol. 2008;158:771-2. (Pubitemid 351639617)
7. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-3.
8. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-4. (Pubitemid 46768841)
9. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-4. (Pubitemid 47435331)
10. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351-5. (Pubitemid 46776140)
11. Kim TD, Schwarz M, Nogai H, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20:1209-14.
12. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95:881-7. (Pubitemid 34839681)
13. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome - positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008;14:5325-31.